07:24 AM EDT, 09/20/2024 (MT Newswires) -- Novo Nordisk ( NVO ) said Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended a label update for obesity drug Wegovy to reflect reduced symptoms and improved physical function in people with obesity-related heart failure with preserved ejection fraction.

The committee's positive opinion is based on the results of two studies showing "greater reductions in heart failure-related symptoms and greater improvements in physical limitations" in patients with obesity-related HFpEF, with or without type 2 diabetes, according to the company.

Additionally, patients taking Wegovy achieved enhanced exercise function as measured by increased 6-minute walking distance at week 52, compared with placebo, the company said.

If approved, this label update would add to a previous update that included data reflecting lower risks of heart attack, stroke and cardiovascular death, Novo Nordisk ( NVO ) said.

Price: 134.00, Change: -0.88, Percent Change: -0.65